Best of cannabinoid science this week...
In a survey of spinal cord injury patients with neuropathic pain, almost 90% reported that cannabis reduced pain intensity by more than 30% & over 80% reported substituting their pain medications with cannabis
A preliminary study evaluating self-reported effects of cannabis and cannabinoids on neuropathic pain and pain medication use in people with spinal cord injury
In cancer patients receiving palliative care, 12.5 milligrams of dronabinol (synthetic THC) improved their cognitive function
Impact of Low-Dose Dronabinol Therapy on Cognitive Function in Cancer Patients Receiving Palliative Care: A Case-Series Intervention Study
In a review of all the patients on the UK Medical Cannabis Registry, they had improvements in self-reported anxiety, sleep quality & higher quality of life, with those using dried flower the most likely to show a clinical improvement
An observational study of clinical outcome measures in patients treated with cannabis-based medicinal products on the UK Medical Cannabis Registry
And in the subset of patients with ADHD, they also reported improvements in anxiety, sleep quality & quality of life
UK Medical Cannabis Registry: An analysis of clinical outcomes of medicinal cannabis therapy for attention-deficit/hyperactivity disorder
In people with psoriasis, topical cannabinoids combined well with a polyherbal formulation for lowering psoriasis symptoms
Therapeutic Potential of Topical Cannabis for the Treatment of Psoriasis: A Preliminary Clinical Evaluation of Two Different Formulations
A survey of epilepsy caregivers found that 93% planned to continue using CBD, primarily because of reduced seizures but also for quality of life improvements
Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey
A thesis project on CBD's regulation of a microRNA as a target to control the brain excitability of seizures (and see an interview with the researcher here)
A Cannabidiol-Regulated MicroRNA Controls Brain Excitability and is a Target for Seizure Control
For skin diseases, a review on the promises of cannabinoid receptors for the treatment of eczema, psoriasis, acne, pruritus, hair disorders & skin cancer
Cannabinoids and Their Receptors in Skin Diseases
For osteoporosis, a review of targeting the endocannabinoid system for treatment
Effect of endocannabinoid system on senile osteoporosis
A review of the neuroprotective & anti-neuroinflammation effects of cannabis & the potential entourage effect between its components
Elucidating the Neuroinflammatory and Neuroprotective Activity of Phytochemicals in Cannabis sativa and their potential Entourage Effects
In rats trained to discriminate benzodiazepines (ie: Valium, Xanax), high levels of CBD made them think they were getting benzos
Discriminative-stimulus effects of cannabidiol oil in Sprague-Dawley rats
In a rat model of anxiety, CBD lessened their anxiety & panic-like behaviors
A cannabidiol (CBD) oral lipid-based nanoemulsion induces anxiolytic- and panicolytic-like effects and increases delta-FosB immunoreactivity in serotonergic cells of the dorsal raphe lateral wings
In mice mast cells (which store histamine), CBD lowered anaphylaxis (a severe allergic reaction)
Cannabidiol Inhibits IgE-Mediated Mast Cell Degranulation and Anaphylaxis in Mice
In a rat model of Parkinson's disease, CBD & CBG - whether given separately or together - decreased L-DOPA medication’s dyskinesia (involuntary erratic movements caused by high dopamine levels)
CANNABIDIOL AND CANNABIGEROL LIMIT L-DOPA-INDUCED DYSKINESIA WHEN GIVEN SEPARATELY OR IN COMBINATION TO HEMIPARKINSONIAN RATS
In a mouse model of catalepsy (frozenness) from the antipsychotic drug haloperidol, the combination of CBD & CBG helped at their lowest doses, though high doses of CBG seem to block CBD efficacy via a serotonin receptor
COULD THE COMBINATION OF TWO NON-PSYCHOTROPIC CANNABINOIDS COUNTERACT HALOPERIDOL CATALEPSY? EFFECTIVENESS OF CANNABIDIOL ASSOCIATED WITH CANNABIGEROL
In a mouse model of Alzheimer's, two of the pinene terpenes caused neuroprotection via lowering the amyloid plaques
Characterizing cannabis-prevalent terpenes for neuroprotection reveal a role for α and β-pinenes in mitigating amyloid β-evoked neurotoxicity and aggregation in vitro
And cannabis terpenes may be causing their painkilling effects via ion channels in the neurons
Terpenes in Cannabis sativa Inhibit Capsaicin Responses in Rat DRG Neurons via Na+/K+ ATPase Activation